Blue Cross, BCN commercial members to have preferred hereditary angioedema drugs, starting Nov. 1

Currently, all hereditary angioedema, or HAE, medications require prior authorization for Blue Cross Blue Shield of Michigan and Blue Care Network commercial members. Starting Nov. 1, 2020, Blue Cross and BCN will require their commercial PPO and HMO members to use preferred HAE drugs for acute treatment and preventive therapy.

For commercial members currently receiving a nonpreferred HAE drug:

• They’re authorized to continue their current therapy through Oct. 31, 2020.
• We’ve proactively authorized therapy with preferred medications from Nov. 1, 2020, through Oct. 31, 2021, to prevent interruptions in care.
• We encourage you to talk with our members to discuss any concerns they may have with the transition.
• We’ll be mailing letters to notify our Blue Cross and BCN members of these changes.

For HAE therapy covered under the medical benefit, the requirements outlined here apply only to groups currently participating in the standard commercial Medical Drug Prior-Authorization Program. Proactive authorizations for preferred drugs apply to members who have their pharmacy benefit with Blue Cross or BCN.

More information
For more information on requirements related to drugs for our commercial members, see:

• Medical benefit requirements
• Pharmacy benefit requirements